

About Albemarle Asset Management

Albemarle Asset Management was founded in London in 2003. The company provides both individual and collective management services for private and institutional investors, financial and capital management consultancy, and managed investment solutions. Our services cover global financial markets and our expertise enables us to offer diverse set of investment instruments and strategies.

Performance

	YTD	1M	3YR	5YR	Inception
Fund	1.54%	-0.90%	20.48%	55.17%	131.25%
Benchmark	7.18%	-2.52%	15.57%	29.46%	70.51%
	Best Mth	Worst Mth	CAGR	Vol	Sharpe R.
Fund	18.26%	-23.04%	6.45%	13.48%	O.51
Benchmark	15.35%	-15.56%	4.06%	12.66%	0.92

Chart Performance



Returns



Fund Objective

Albemarle Target Europe Fund is a sub-fund of Albemarle Funds Plc an open-ended investment company with variable capital incorporated in Ireland. The investment objective of the subfund is to achieve long term capital appreciation by investing in the European equity market.

Fund Information

Company	Albemarle Funds Plc
Investment Manager	Albemarle Asset Management Ltd
Bloomberg	ATLTEUI ID
ISIN	IEOOB502PK59
Inception	21/01/2011
Currency	EUR
Fund Manager	Albemarle Asset Management Ltd
Management Fees	0.80% p.a.
Benchmark	MSCI EMU
Performance Fees	25% of the value which exceeds the
	benchmark return of the MSCI EMU
	Index
NAV	Daily
Cut-Off	T-1 before 1pm Irish Ti The Fund posted
Stlmt date for sub.	T+2 Irish Business Days
StImt date for red.	T+2 Irish Business Days
Domicile	Ireland
Auditors	Grant Thornton
Depositary	Northern Trust Fiduciary Services
	(Ireland) Ltd
Category	UCITS V
5 ,	

Important Information

The information contained within this document is for the use of Institutional and Professional Investors only

Source: Bloomberg

Different Share Classes

Class	NAV	YTD	1M	3YR	5YR	Since Inception	Inception Date	Management Fee
Α	Daily	1.26%	-0.96%	18.32%	50.86%	121.86%	15/12/2010	1.8% p.a.







Top Holdings

Total		23.98%
JUNG	GHEINRICH - PRFD	3.94%
INTER	RPUMP GROUP SPA	4.08%
FLUIE	DRA SA	4.67%
EL.EN	N. SPA	5.08%
FILA	SPA	6.21%





Country Breakdown Net Exposure



Commentary

The Fund posted a small negative performance in April, outperforming its benchmark by c. +150bps. The main positive contributors to the Fund performance had been Fila, Stratec, Synergie, Ebro Foods and Marr. Fila outperformed as the stock fully recovered the decline registered at the end of March after underwhelming 2023 results and soft 2024 guidance, also thanks to some speculation regarding the possible delisting of the company by the majority shareholder. Synergie rose as the French human resources management company announced 2023 results and 2024 sales outlook in line with estimates, and it announced a new acquisition in Australia. Ebro gained as the Spanish food producer posted Q1 2024 results ahead of expectations showing a pace of earnings growth well ahead of the full-year guidance. The main detractors to the Fund performance during the month had been Fluidra, Interpump, Komax, Esprinet and Mersen. Fluidra declined in line with its US competitors as a soft start of the year (also due to adverse weather) and still depressed new-built activity should weight on Q1 2024 results. Interpump underperformed as the continuing weak momentum in manufacturing activity especially in Europe is casting some doubts about the forecasted second half recovery and the feasibility of the 2024 guidance. Komax declined as the Swiss industrial company was hit by a double downgrade from a broker which anticipates a sharp drop in first-half profits because of the weak European automotive market and tough comparatives. During the month the main trades executed had been the sale of Acerinox, Corticeira Amorim, Lacroix, Synergie and Duerr, and the purchase of Landis+Gyr, Jost, Interpump, Jenoptik, Fluidra and Dometic.

Disclaimer

This information is being communicated by Albemarle Asset Management Limited, which is authorised and regulated by the Financial Conduct Authority. This material is for information only and does not constitute an offer or recommendation to buy or sell any investment, or subscribe to any investment management or advisory service. It is only directed and may only be distributed to persons who are Professional Clients or Eligible Counterparties and is not, under any circumstances, intended for distribution to the general public. With investment, your capital is at risk and the value of an investment and the income from it can go up as well as down, it may be affected by exchange rate variations and you may not get back the amount invested. Past performance is not necessarily a guide to future performance. We do not represent that this information, including any third party information, is accurate or complete and it should not be relied upon as such. Opinions expressed herein reflect the opinion of Albemarle Asset Management Limited and are subject to change without notice. No part of this document may be reproduced in any manner without the written permission of Albemarle Asset Management Limited, however recipients may pass on this document but only to others falling within this category. This information should be read in conjunction with the relevant fund documentation which may include the fund's prospectus, simplified prospectus or supplement documentation and if you are unsure if any of the products and portfolios featured are the right choice for you, please seek independent financial advice provided by regulated third parties.